Over the past ten years, the biosimilars market has rapidly advanced, mainly due to the forthcoming patent expiry of several blockbuster biologics and its potential to alleviate the economic burden of costly biologic treatments on healthcare systems. Despite the attractiveness of the biosimilars space, manufacturers must account for the not-insignificant development and commercialization hurdles in the process to market entry. Substantial capital investment and expertise in biological development and manufacturing is mandatory.
Biosimilars developers should be aware of alternative options when they lack in-house manufacturing capabilities, be well informed of the steps for designing biosimilars clinical trials, and be familiarized with the local regulatory framework and reimbursement landscape in the markets of interest. Moreover, with the growing number of approved biosimilars, it is paramount that brand innovator companies focus on developing more creative strategies to differentiate their product and guard against biosimilar competition, either through development of next-generation biologics, patent litigation, or pricing negotiations.
In the infographic below, DRG’s Biosimilars experts assess corporate strategies – based on recent examples – that companies can employ to flourish in competitive global markets.
Key business insights our Biosimilars experts and research address:
Reach out for more information on our Biosimilars insights, including how pharma companies stay ahead of the competition in this highly competitive market.